BMY Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 0.58% compared to Bristol-Myers Squibb's net margin of 23.56%. Bristol-Myers Squibb's return on equity of -46.27% beat Gilead Sciences's return on equity of 2.5%.

Bristol-Myers Squibb has a consensus price target of $61.24, signalling upside risk potential of 3.98%. On the other hand Gilead Sciences has an analysts' consensus of $111.71 which suggests that it could grow by 0.49%. Given that Bristol-Myers Squibb has higher upside potential than Gilead Sciences, analysts believe Bristol-Myers Squibb is more attractive than Gilead Sciences.

Bristol-Myers Squibb has a beta of 0.435, which suggesting that the stock is 56.528% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.213, suggesting its less volatile than the S&P 500 by 78.702%.

Bristol-Myers Squibb has a quarterly dividend of $0.62 per share corresponding to a yield of 4.11%. Gilead Sciences offers a yield of 2.79% to investors and pays a quarterly dividend of $0.79 per share. Bristol-Myers Squibb pays -54.35% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Bristol-Myers Squibb quarterly revenues are $12.3B, which are larger than Gilead Sciences quarterly revenues of $7.6B. Bristol-Myers Squibb's net income of $72M is lower than Gilead Sciences's net income of $1.8B. Notably, Bristol-Myers Squibb's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 300.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.47x versus 4.86x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 0.58% compared to Bristol-Myers Squibb's net margin of 15.24%. Bristol-Myers Squibb's return on equity of -46.27% beat Johnson & Johnson's return on equity of 19.98%.

Bristol-Myers Squibb has a consensus price target of $61.24, signalling upside risk potential of 3.98%. On the other hand Johnson & Johnson has an analysts' consensus of $169.07 which suggests that it could grow by 3.64%. Given that Bristol-Myers Squibb has higher upside potential than Johnson & Johnson, analysts believe Bristol-Myers Squibb is more attractive than Johnson & Johnson.

Bristol-Myers Squibb has a beta of 0.435, which suggesting that the stock is 56.528% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.473, suggesting its less volatile than the S&P 500 by 52.686%.

Bristol-Myers Squibb has a quarterly dividend of $0.62 per share corresponding to a yield of 4.11%. Johnson & Johnson offers a yield of 3.04% to investors and pays a quarterly dividend of $1.24 per share. Bristol-Myers Squibb pays -54.35% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bristol-Myers Squibb quarterly revenues are $12.3B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Bristol-Myers Squibb's net income of $72M is lower than Johnson & Johnson's net income of $3.4B. Notably, Bristol-Myers Squibb's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 28.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.47x versus 4.46x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 0.58% compared to Bristol-Myers Squibb's net margin of 32.59%. Bristol-Myers Squibb's return on equity of -46.27% beat Eli Lilly and's return on equity of 80.24%.

Bristol-Myers Squibb has a consensus price target of $61.24, signalling upside risk potential of 3.98%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 22.98%. Given that Eli Lilly and has higher upside potential than Bristol-Myers Squibb, analysts believe Eli Lilly and is more attractive than Bristol-Myers Squibb.

Bristol-Myers Squibb has a beta of 0.435, which suggesting that the stock is 56.528% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

Bristol-Myers Squibb has a quarterly dividend of $0.62 per share corresponding to a yield of 4.11%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Bristol-Myers Squibb pays -54.35% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bristol-Myers Squibb quarterly revenues are $12.3B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Bristol-Myers Squibb's net income of $72M is lower than Eli Lilly and's net income of $4.4B. Notably, Bristol-Myers Squibb's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 70.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.47x versus 16.49x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 0.58% compared to Bristol-Myers Squibb's net margin of 23.96%. Bristol-Myers Squibb's return on equity of -46.27% beat Merck &'s return on equity of 40.25%.

Bristol-Myers Squibb has a consensus price target of $61.24, signalling upside risk potential of 3.98%. On the other hand Merck & has an analysts' consensus of $112.07 which suggests that it could grow by 27.93%. Given that Merck & has higher upside potential than Bristol-Myers Squibb, analysts believe Merck & is more attractive than Bristol-Myers Squibb.

Bristol-Myers Squibb has a beta of 0.435, which suggesting that the stock is 56.528% less volatile than S&P 500. In comparison Merck & has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.24%.

Bristol-Myers Squibb has a quarterly dividend of $0.62 per share corresponding to a yield of 4.11%. Merck & offers a yield of 3.61% to investors and pays a quarterly dividend of $0.81 per share. Bristol-Myers Squibb pays -54.35% of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bristol-Myers Squibb quarterly revenues are $12.3B, which are smaller than Merck & quarterly revenues of $15.6B. Bristol-Myers Squibb's net income of $72M is lower than Merck &'s net income of $3.7B. Notably, Bristol-Myers Squibb's price-to-earnings ratio is -- while Merck &'s PE ratio is 13.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.47x versus 3.47x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.